Michael G. King Jr. - 21 Feb 2024 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: SABS
Reported as of: 21 Feb 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Feb 2024, 16:45:19 UTC
Prior SEC filing: 30 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Michael G. King, Jr.

Key filing fact

Michael G. King Jr. filed Form 4 for SAB Biotherapeutics, Inc. (SABS) on 23 Feb 2024.

Key facts

This page summarizes Michael G. King Jr.'s Form 4 filing for SAB Biotherapeutics, Inc. (SABS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Feb 2024, 16:45.

Change

Previous filing in this sequence was filed on 30 Nov 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SABS transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +115,000
Change %
Price: $0.000000
Shares after: 115,000
Date: 21 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 115,000
Exercise price: $5.17
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents options to purchase shares of common stock pursuant to the Company's 2014 Equity Incentive Plan.

Footnote F2

The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.